Daniel Atar
Impact in
- Oncology top 10%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
-
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
Papers in
- Oncology 10
- CAR-T cell therapy research 10
-
- Cytomegalovirus and herpesvirus research 1
- Inflammatory Myopathies and Dermatomyositis 1
- Co-authors
- Christian Martin Seitz (5 shared papers)Claudia Lengerke (2 shared papers)Marius Horger (1 shared paper)Christoph Faul (1 shared paper)K. Lutz (1 shared paper)Antje Bornemann (1 shared paper)Rebekka Schairer (1 shared paper)Wolfgang Andreas Bethge (1 shared paper)
In The Last Decade
Daniel Atar
12 papers receiving 460 citations
Daniel Atar's Hit Papers
Peers
Comparison fields: 5 of 32
- Oncology 306
- Immunology 66
- Hematology 24
- Epidemiology 50
- Rheumatology 21
Countries citing papers authored by Daniel Atar
This map shows the geographic impact of Daniel Atar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Atar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Atar more than expected).
Fields of papers citing papers by Daniel Atar
This network shows the impact of papers produced by Daniel Atar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Atar. The network helps show where Daniel Atar may publish in the future.
Co-authors
The 25 scholars most cited alongside Daniel Atar, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome Hit paper breakdown → | 2023 | 178 |
| 2 | 2019 | 74 | |
| 3 | 2023 | 50 | |
| 4 | 2022 | 40 | |
| 5 | 2021 | 37 | |
| 6 | 2024 | 28 | |
| 7 | 2019 | 17 | |
| 8 | 2021 | 13 | |
| 9 | 2022 | 13 | |
| 10 | 2024 | 10 | |
| 11 | 2023 | 7 | |
| 12 | 2022 | 5 | |
| 13 | 2026 | 0 |
About Daniel Atar
Daniel Atar is a scholar working on Oncology, Epidemiology, Hematology, Neurology and Immunology, having authored 13 papers that have together received 472 indexed citations. Recurring topics across this work include CAR-T cell therapy research (10 papers), Cytomegalovirus and herpesvirus research (1 paper), Monoclonal and Polyclonal Antibodies Research (1 paper), Virus-based gene therapy research (1 paper), Immune Cell Function and Interaction (1 paper), Neuroblastoma Research and Treatments (1 paper), Hematopoietic Stem Cell Transplantation (1 paper) and Inflammatory Myopathies and Dermatomyositis (1 paper). The work is most often cited by research in Oncology (306 citations), Immunology (66 citations), Hematology (24 citations), Epidemiology (50 citations) and Rheumatology (21 citations). Daniel Atar has collaborated with scholars based in Germany and Australia. Frequent co-authors include Christian Martin Seitz, Claudia Lengerke, Marius Horger, Christoph Faul, K. Lutz, Antje Bornemann, Rebekka Schairer, Wolfgang Andreas Bethge, Rupert Handgretinger and Jörg Henes. Their work appears in journals such as OncoImmunology, Leukemia, Frontiers in Immunology, Science Translational Medicine and JAMA.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.